LinkOPH

SAN DIEGO — Optimal management of macular holes has long been debated, but some conclusions can be made, according to a speaker at the American Society of Retina Specialists annual meeting. Ron Adelman, MD, MPH, FACS, who presented results from the European Vitreoretinal Society Macular Hole Study, said despite the number of variables regarding technique and management among the 140 participating retina specialists in 28 countries, hole closure was achieved in 85.7% of 4,207 macular hole cases after more than 1 year of follow-up.

Read more →

SAN DIEGO – Face-down posturing made no difference in recovery after macular hole surgery, according to a speaker here.Using data from the first 400 cases entered in prospective registry-style audit database of patients undergoing macular hole repair in Australia, Alex Hunyor, MD, and colleagues determined that no posturing was noninferior to face-down posturing with regard to outcomes.

Read more →

SAN DIEGO — Repeat injections of dexamethasone intravitreal implant have no cumulative effect on IOP, and the rate of high IOP spikes is low, according to a speaker here. The MEAD study, which was the basis for the recent U.S. Food and Drug Administration approval of Ozurdex (dexamethasone intravitreal implant, Allergan) for treatment of diabetic macular edema (DME) in patients who are pseudophakic or scheduled for cataract surgery, also demonstrated the adverse effect of increased IOP in 36% of treated patients.

Read more →

SAN DIEGO — Patients with diabetic macular edema receive fewer intravitreal anti-VEGF injections in clinical practice than in published clinical trials, with consequently less visual acuity improvement, according to a speaker here. Nancy M. Holekamp, MD, and colleagues looked at large national claims databases to determine real-world treatment of diabetic macular edema and found that patients receive two to three anti-VEGF injections in a 12-month period.

Read more →